Literature DB >> 19509258

The Pyk2 FERM domain as a target to inhibit glioma migration.

Joseph C Loftus1, Zhongbo Yang, Nhan L Tran, Jean Kloss, Carole Viso, Michael E Berens, Christopher A Lipinski.   

Abstract

The invasion of malignant glioma cells into the surrounding normal brain precludes effective clinical treatment. In this report, we investigated the role of the NH(2)-terminal FERM domain in the regulation of the promigratory function of Pyk2. We report that the substitution of residues that constitute a small cleft on the surface of the F3 module of the FERM domain do not significantly alter Pyk2 expression but result in the loss of Pyk2 phosphorylation. A monoclonal antibody, designated 12A10, specifically targeting the Pyk2 FERM domain was generated and recognizes an epitope located on the beta5C-alpha1C surface of the F3 module of the FERM domain. Amino acid substitutions in the F3 module that resulted in the loss of Pyk2 phosphorylation also inhibited the binding of 12A10, suggesting that the 12A10 epitope overlaps a site that plays a role in Pyk2 activity. Conjugation of 12A10 to a membrane transport peptide led to intracellular accumulation and inhibition of glioma cell migration in a concentration-dependent manner. A single chain Fv fragment of 12A10 was stable when expressed in the intracellular environment, interacted directly with Pyk2, reduced Pyk2 phosphorylation, and inhibited glioma cell migration in vitro. Stable intracellular expression of the 12A10 scFv significantly extended survival in a glioma xenograft model. Together, these data substantiate a central role for the FERM domain in regulation of Pyk2 activity and identify the F3 module as a novel target to inhibit Pyk2 activity and inhibit glioma progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509258      PMCID: PMC3180876          DOI: 10.1158/1535-7163.MCT-08-1055

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  49 in total

Review 1.  Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins.

Authors:  S Tsukita; S Yonemura
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

2.  Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain.

Authors:  M A Pearson; D Reczek; A Bretscher; P A Karplus
Journal:  Cell       Date:  2000-04-28       Impact factor: 41.582

3.  Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases.

Authors:  Y J Zhou; M Chen; N A Cusack; L H Kimmel; K S Magnuson; J G Boyd; W Lin; J L Roberts; A Lengi; R H Buckley; R L Geahlen; F Candotti; M Gadina; P S Changelian; J J O'Shea
Journal:  Mol Cell       Date:  2001-11       Impact factor: 17.970

4.  Chemical engineering of cell penetrating antibodies.

Authors:  Y Zhao; D Lou; J Burkett; H Kohler
Journal:  J Immunol Methods       Date:  2001-08-01       Impact factor: 2.303

Review 5.  RAFTK/Pyk2-mediated cellular signalling.

Authors:  H Avraham; S Y Park; K Schinkmann; S Avraham
Journal:  Cell Signal       Date:  2000-03       Impact factor: 4.315

6.  Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3' to 5' exonuclease activity.

Authors:  Z Wang; M Raifu; M Howard; L Smith; D Hansen; R Goldsby; D Ratner
Journal:  J Immunol Methods       Date:  2000-01-13       Impact factor: 2.303

7.  The 2.7 A crystal structure of the activated FERM domain of moesin: an analysis of structural changes on activation.

Authors:  S D Edwards; N H Keep
Journal:  Biochemistry       Date:  2001-06-19       Impact factor: 3.162

8.  Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-F(c) intrabodies.

Authors:  Randall W Strube; Si-Yi Chen
Journal:  J Immunol Methods       Date:  2002-05-01       Impact factor: 2.303

9.  Inhibition of the calcium-dependent tyrosine kinase (CADTK) blocks monocyte spreading and motility.

Authors:  J M Watson; T W Harding; V Golubovskaya; J S Morris; D Hunter; X Li; J S Haskill; H S Earp
Journal:  J Biol Chem       Date:  2000-11-02       Impact factor: 5.157

10.  Determinants of human astrocytoma migration.

Authors:  A Giese; M D Rief; M A Loo; M E Berens
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

View more
  21 in total

1.  Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival.

Authors:  Ssang-Taek Lim; Nichol L G Miller; Ju-Ock Nam; Xiao Lei Chen; Yangmi Lim; David D Schlaepfer
Journal:  J Biol Chem       Date:  2009-10-30       Impact factor: 5.157

2.  Dynamin and PTP-PEST cooperatively regulate Pyk2 dephosphorylation in osteoclasts.

Authors:  Pierre P Eleniste; Liping Du; Mahesh Shivanna; Angela Bruzzaniti
Journal:  Int J Biochem Cell Biol       Date:  2012-02-08       Impact factor: 5.085

3.  TROY (TNFRSF19) is overexpressed in advanced glial tumors and promotes glioblastoma cell invasion via Pyk2-Rac1 signaling.

Authors:  Vincent M Paulino; Zhongbo Yang; Jean Kloss; Matthew J Ennis; Brock A Armstrong; Joseph C Loftus; Nhan L Tran
Journal:  Mol Cancer Res       Date:  2010-09-29       Impact factor: 5.852

4.  The Pyk2 FERM regulates Pyk2 complex formation and phosphorylation.

Authors:  Daniel Riggs; Zhongbo Yang; Jean Kloss; Joseph C Loftus
Journal:  Cell Signal       Date:  2010-09-16       Impact factor: 4.315

5.  Extracellular ATP stimulates epithelial cell motility through Pyk2-mediated activation of the EGF receptor.

Authors:  Ethan R Block; Michael A Tolino; Jes K Klarlund
Journal:  Cell Signal       Date:  2011-08-04       Impact factor: 4.315

Review 6.  Targeting Pyk2 for therapeutic intervention.

Authors:  Christopher A Lipinski; Joseph C Loftus
Journal:  Expert Opin Ther Targets       Date:  2010-01       Impact factor: 6.902

7.  Structural conservation in band 4.1, ezrin, radixin, moesin (FERM) domains as a guide to identify inhibitors of the proline-rich tyrosine kinase 2.

Authors:  Nathalie Meurice; Lei Wang; Christopher A Lipinski; Zhongbo Yang; Christopher Hulme; Joseph C Loftus
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

8.  A Novel Signaling Complex between TROY and EGFR Mediates Glioblastoma Cell Invasion.

Authors:  Zonghui Ding; Alison Roos; Jean Kloss; Harshil Dhruv; Sen Peng; Patrick Pirrotte; Jennifer M Eschbacher; Nhan L Tran; Joseph C Loftus
Journal:  Mol Cancer Res       Date:  2017-11-08       Impact factor: 5.852

9.  Proliferation and migration of tumor cells in tapered channels.

Authors:  Yuan Wan; Deepika Tamuly; Peter B Allen; Young-Tae Kim; Robert Bachoo; Andrew D Ellington; Samir M Iqbal
Journal:  Biomed Microdevices       Date:  2013-08       Impact factor: 2.838

10.  TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance.

Authors:  Joseph C Loftus; Harshil Dhruv; Serdar Tuncali; Jean Kloss; Zhongbo Yang; Cassie A Schumacher; Brian Cao; Bart O Williams; Jennifer M Eschbacher; Julianna T D Ross; Nhan L Tran
Journal:  Mol Cancer Res       Date:  2013-05-22       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.